On January 13, 2026, China SXT Pharmaceuticals, Inc. completed a securities purchase agreement, resulting in a gross proceeds of approximately $9.11 million from the sale of 12 million Class A ordinary shares and pre-funded warrants for 54.67 million shares at $0.001 exercise price.